Sugi Predict

Sugi Predict / Compounds / SCHEMBL3930544

SCHEMBL3930544

SCHEMBL3930544

NCC1(N2CCCCC2)CCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.36
▸ GAA P10253 2/20 0.36
▸ RAD52 P43351 1/20 0.36
▸ MEN1 O00255 4/20 0.36
▸ SIGMAR1 Q99720 3/20 0.34
▸ RAB9A P51151 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MC4R P32245 1/20 0.33
▸ GRIN2D O15399 1/20 0.33
▸ GRIN3B O60391 1/20 0.33
▸ CYP2B6 P20813 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ PRCP P42785 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ GRIN2A Q12879 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ GRIN2C Q14957 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL553125 1.00 KMT2A (0.36) KMT2AGAARAD52MEN1SIGMAR1
SCHEMBL31441143 1.00 KMT2A (0.36) KMT2AGAARAD52MEN1SIGMAR1
Hydrochloric Acid SCHEMBL1828960 0.98 OPRM1 (0.35) KMT2AGAARAD52MEN1SIGMAR1
SCHEMBL25165704 0.97 KMT2A (0.37) KMT2AGAARAD52MEN1SIGMAR1
SCHEMBL8265735 0.97 KMT2A (0.37) KMT2AGAARAD52MEN1SIGMAR1
SCHEMBL16757065 0.95 KMT2A (0.36) KMT2AGAARAD52MEN1SIGMAR1
SCHEMBL470816 0.95 KMT2A (0.36) KMT2AGAARAD52MEN1SIGMAR1
SCHEMBL4590548 0.90 GAA (0.38) KMT2AGAARAD52KCNH2
SCHEMBL30699749 0.87 GAA (0.37) KMT2AGAARAD52
SCHEMBL16143384 0.82 GAA (0.50) KMT2AGAARAD52SIGMAR1MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049536-A2 POLYCYCLIC VIRAL INHIBITORS GENELABS TECHNOLOGIES, INC. (US) 2009-04-22 — — EP claimed
EP-2044083-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2009-04-08 — — EP claimed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 — — US claimed
US-20080045498-A1 POLYCYCLIC VIRAL INHIBITORS GENELABS TECHNOLOGIES, INC. 2008-02-21 — — US claimed
WO-2008011521-A2 POLYCYCLIC VIRAL INHIBITORS GENELABS TECHNOLOGIES, INC. (US) 2008-01-24 — — WO claimed
WO-2008008912-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 — — WO claimed
WO-2008008907-A2 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 — — WO claimed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 — — US claimed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 — — US disclosed
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 — — US disclosed
US-11214548-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2022-01-04 — — US disclosed
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-06-24 — — US disclosed
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2020-03-12 — — US disclosed
CN-110709085-A Compounds and methods for treating visceral pain 艾尼纳制药公司 2020-01-17 — — CN disclosed
WO-2008011521-A2 POLYCYCLIC VIRAL INHIBITORS GENELABS TECHNOLOGIES, INC. (US) 2008-01-24 — — WO disclosed
WO-2008008912-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 — — WO disclosed
WO-2008008907-A2 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 — — WO disclosed
EP-1844042-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2007-10-17 — — EP disclosed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 — — US disclosed
WO-2006076529-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2006-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045498-A1 POLYCYCLIC VIRAL INHIBITORS EIF2AK2, ZC3HAV1, MAVS KMT2A 2119/4885GAA 176/4885RAD52 3803/4885
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 KMT2A 2781/4885GAA 718/4885RAD52 4477/4885
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses HAVCR2, ZC3HAV1, SARS1 KMT2A 2460/4885GAA 774/4885RAD52 2382/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 KMT2A 2962/4885GAA 3665/4885RAD52 3678/4885
US-11214548-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 KMT2A 2962/4885GAA 3665/4885RAD52 3678/4885
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 KMT2A 4254/4885GAA 66/4885RAD52 2622/4885
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 KMT2A 2781/4885GAA 718/4885RAD52 4477/4885
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 KMT2A 2962/4885GAA 3665/4885RAD52 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.